Page 575 - Hematology_ Basic Principles and Practice ( PDFDrive )

490 Part V Red Blood Cells

comparable to that of deferoxamine. 16,26 The most common adverse 7. Powers JM, Buchanan GR: Diagnosis and management of iron deficiency
events have been rash, gastrointestinal disturbances, and abnormali- anemia. Hematol Oncol Clin North Am 28:729–745, vi, 2014.
ties in renal function. Additional clinical studies examining the 8. Heeney MM, Finberg KE: Iron-refractory iron deficiency anemia
long-term safety and efficacy of deferasirox are in progress, but the (IRIDA). Hematol Oncol Clin North Am 28:637–652, v, 2014.
initial experience with this drug suggests that this orally active, iron- 9. DeLoughery TG: Microcytic anemia. N Engl J Med 371:1324–1331,
chelating agent is a well-tolerated, once-daily treatment for control 2014.
of transfusional iron overload. Most patients now opt for deferasirox 10. Thomas DW, Hinchliffe RF, Briggs C, et al: Guideline for the laboratory
because of the ease of oral administration. diagnosis of functional iron deficiency. Br J Haematol 161:639–648,
2013.
11. Bailie GR, Verhoef JJ: Differences in the reporting rates of serious allergic
Prognosis adverse events from intravenous iron by country and population. Clin
Adv Hematol Oncol 10:101–108, 2012.
The prognosis for patients with iron overload is influenced by many 12. Camaschella C: Treating iron overload. N Engl J Med 368:2325–2327,
factors, including the magnitude, rate, and route of iron loading; 2013.
distribution of iron deposition between reticuloendothelial macro- 13. Bardou-Jacquet E, Brissot P: Diagnostic evaluation of hereditary
phage and parenchymal sites; amount and duration of exposure to hemochromatosis (HFE and non-HFE). Hematol Oncol Clin North Am
circulating nontransferrin-bound iron; ascorbate status; and coexist- 28:625, 2014.
ing disorders, especially alcoholism. 14,15 The magnitude of iron 14. Barton JC: Hemochromatosis and iron overload: from bench to clinic.
accumulation seems to be a critical determinant of the risk of cirrhosis Am J Med Sci 346:403–412, 2013.
of the liver and, in turn, of hepatocellular carcinoma, now the two 15. Ekanayake D, Roddick C, Powell LW: Recent advances in hemochroma-
major causes of death in HFE hemochromatosis. If the disease is tosis: a 2015 update: a summary of proceedings of the 2014 conference
diagnosed before tissue injury occurs, phlebotomy therapy to remove held under the auspices of Hemochromatosis Australia. Hepatol Int
the excess iron can prevent all of the complications of hemochroma- 9:174–182, 2015.
tosis, including cirrhosis, and return the patient’s life expectancy to 16. Brittenham GM: Iron-chelating therapy for transfusional iron overload.
normal. 14,15 Even if organ damage is present, phlebotomy prevents N Engl J Med 364:146–156, 2011.
further progression, and amelioration of some features of the disease 17. McDonald CJ, Wallace DF, Crawford DH, et al: Iron storage disease
is possible. Skin pigmentation diminishes; hepatic function may in Asia-Pacific populations: the importance of non-HFE mutations.
improve while fibrosis is arrested or sometimes regresses; and cardiac J Gastroenterol Hepatol 28:1087–1094, 2013.
abnormalities, including even cardiac failure, may resolve. Diabetes 18. Bardou-Jacquet E, Ben Ali Z, Beaumont-Epinette MP, et al: Non-HFE
and other endocrine abnormalities usually are ameliorated only hemochromatosis: pathophysiological and diagnostic aspects. Clin Res
slightly, if at all, although reversal of hypogonadism has occurred. Hepatol Gastroenterol 38:143–154, 2014.
Arthropathy usually does not subside and may even continue to 19. Bottomley SS, Fleming MD: Sideroblastic anemia: diagnosis and man-
progress despite phlebotomy. agement. Hematol Oncol Clin North Am 28:653, 2014.
In patients with iron overload who cannot be treated by phle- 20. Meyer E, Kurian MA, Hayflick SJ: Neurodegeneration with brain iron
botomy, chelation therapy is effective in reducing the body iron accumulation: genetic diversity and pathophysiological mechanisms.
burden and improving the prognosis. 16,26 Orally administered defera- Annu Rev Genomics Hum Genet 16:257, 2015.
sirox or chronic infusion of parenteral deferoxamine decreases the 21. Jenkitkasemwong S, Wang CY, Coffey R, et al: SLC39A14 is required
hepatic iron concentration, improves hepatic function, promotes for the development of hepatocellular iron overload in murine models
growth and sexual maturation, and helps protect against cardiac of hereditary hemochromatosis. Cell Metab 22:138, 2015.
disease and early death. In all forms of iron overload, the most 22. Brissot P, Ropert M, Le Lan C, et al: Non-transferrin bound iron:
effective means of preventing complications is prevention of iron a key role in iron overload and iron toxicity. Biochim Biophys Acta
accumulation, either by early identification and phlebotomy treat- 1820:403–410, 2012.
ment of hereditary hemochromatosis or by early institution of chela- 23. McLaren CE, Emond MJ, Subramaniam VN, et al: Exome sequencing
tion therapy in patients with iron-loading or transfusion-dependent in HFE C282Y homozygous men with extreme phenotypes identifies a
anemia. GNPAT variant associated with severe iron overload. Hepatology 62:429,
2015.
24. Rouault TA: Iron metabolism in the CNS: implications for neurodegen-
REFERENCES erative diseases. Nat Rev Neurosci 14:551–564, 2013.
25. Wu XG, Wang Y, Wu Q, et al: HFE interacts with the BMP type I
1. Ganz T: Systemic iron homeostasis. Physiol Rev 93:1721–1741, 2013. receptor ALK3 to regulate hepcidin expression. Blood 124:1335–1343,
2. Lane DJ, Merlot AM, Huang ML, et al: Cellular iron uptake, traffick- 2014.
ing and metabolism: key molecules and mechanisms and their roles in 26. Coates TD: Physiology and pathophysiology of iron in hemoglobin-
disease. Biochim Biophys Acta 1853:1130–1144, 2015. associated diseases. Free Radic Biol Med 72:23–40, 2014.
3. Kautz L, Jung G, Valore EV, et al: Identification of erythroferrone as 27. Kautz L, Jung G, Nemeth E, et al: Erythroferrone contributes to recovery
an erythroid regulator of iron metabolism. Nat Genet 46:678–684, from anemia of inflammation. Blood 124:2569–2574, 2014.
2014. 28. Whitington PF: Gestational alloimmune liver disease and neonatal
4. St Pierre TG, El-Beshlawy A, Elalfy M, et al: Multicenter validation of hemochromatosis. Semin Liver Dis 32:325–332, 2012.
spin-density projection-assisted R2-MRI for the noninvasive measure- 29. Zaloumis SG, Allen KJ, Bertalli NA, et al: Natural history of HFE
ment of liver iron concentration. Magn Reson Med 71:2215–2223, simple heterozygosity for C282Y and H63D: a prospective 12-year study.
2014. J Gastroenterol Hepatol 30:719–725, 2015.
5. Kassebaum NJ, Jasrasaria R, Naghavi M, et al: A systematic analysis of 30. Bowes O, Baxter K, Elsey T, et al: Hereditary hyperferritinaemia cataract
global anemia burden from 1990 to 2010. Blood 123:615–624, 2014. syndrome. Lancet 383:1520, 2014.
6. Camaschella C: Iron-deficiency anemia. N Engl J Med 372:1832–1843,
2015.